{"success":true,"data":{"pressRelease":{"id":"56322","rtpr_id":"nGNX90RHYp","ticker":"WOK","exchange":"NASDAQ","all_tickers":["WOK"],"title":"WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference","author":"Globe Newswire","published_at":"2026-06-05T13:00:01.622Z","article_body":"Deepening Engagement with the Global Biopharmaceutical Community\n\nAuckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical\nTechnology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or\n“we”), a supplier of medical devices in China,today announced its\nparticipation as a partner and exhibitor at the 2026 CBA-China Annual\nConference (the “Conference”), held on May 8 to 10, 2026 in Wuxi, Jiangsu\nProvince, China. The Conference was organized by the Chinese Biopharmaceutical\nAssociation China Branch (CBA-China) and co-hosted by BioValley, bringing\ntogether hundreds of scientists, entrepreneurs, and industry leaders from\nacross the global biopharmaceutical sector.\n\nAs a partner of the Conference, WORK Medical engaged with senior experts from\nNorth America, Europe, and the Asia-Pacific region throughout the three-day\nevent. Discussions focused on global supply chain collaboration, the\napplication of artificial intelligence (“AI”) technologies in life\nsciences, and opportunities for cooperation involving multimodal AI models in\nclinical research and translation.\n\nThe Company’s participation extended beyond showcasing its medical hardware\nand consumables business. WORK Medical also highlighted its strategic\npositioning as a participant in the “AI+Digital Healthcare” sector,\ndemonstrating its evolving focus on AI-driven data enablement and digital\nasset operations. The Company intends to leverage this engagement to establish\nhigh-value strategic partnerships with global industry professionals in areas\nincluding joint technology development and digital asset management.\n\nWORK Medical’s participation in the Conference reflects the Company’s\nbroader strategy of expanding its presence within international professional\nnetworks and strengthening its global industry relationships. The Company\nviews active engagement with the global biopharmaceutical community as an\nimportant component of its international growth strategy, providing insight\ninto emerging clinical needs and facilitating the development of cross-border\npartnerships that may support its future innovation initiatives.\n\nManagement Commentary\n\nMr. Wu Shuang, Chief Executive Officer and Chairman of WORK Medical,\ncommented: “The CBA-China Annual Conference serves as an important platform\nconnecting China’s biopharmaceutical sector with the global scientific\ncommunity. As a Nasdaq-listed company, WORK Medical views continued engagement\nwith leading international medical professionals as an important element of\nour globalization strategy. Through participation in this event, we aim to\nstrengthen our presence within the international professional community,\ndeepen our relationships with industry leaders and gain valuable insight into\nevolving global healthcare trends. We believe these interactions will support\nour efforts to identify future collaboration opportunities and advance our\nlong-term growth strategy.”\n\nAbout WORK Medical Technology Group LTD\n\nWORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou)\nMedical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a\nsupplier of medical devices that develops and manufactures Class I and II\nmedical devices and sells Class I and II disposable medical devices through\noperating subsidiaries in China. The Company has a diverse product portfolio\ncomprising 23 products, including customized and multifunctional masks and\nother medical consumables. All the products have been sold in 34\nprovincial-level administrative regions in China, with 15 of them sold in more\nthan 30 countries worldwide. The Company has received a number of\nquality-related manufacturing designations and has registered 17 products with\nthe U.S. Food and Drug Administration allowing their products to enter the\nU.S. market. For more information, please visit the Company’s website:\nhttps://www.workmedtech.com/corporate.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nmade pursuant to the safe harbor provisions of the Private Securities\nLitigation Reform Act of 1995. These statements may be identified by words\nsuch as “aims,” “anticipates,” “believes,” “could,”\n“estimates,” “expects,” “forecasts,” “goal,” “intends,”\n“may,” “plans,” “possible,” “potential,” “seeks,”\n“will,” and variations of these words or similar expressions that are\nintended to identify forward-looking statements. Any such statements in this\npress release that are not statements of historical fact may be deemed to be\nforward-looking statements. Any forward-looking statements in this press\nrelease are based on the Company’s current expectations, estimates and\nprojections only as of the date of this release and are subject to a number of\nrisks and uncertainties that could cause actual results to differ materially\nand adversely from those set forth in or implied by such forward-looking\nstatements. Although the Company believes that the expectations expressed in\nthese forward-looking statements are reasonable, it cannot assure you that\nsuch expectations will turn out to be correct, and the Company cautions\ninvestors that actual results may differ materially from the anticipated\nresults and encourages investors to review other factors that may affect its\nfuture results set forth in the Company’s annual report on Form 20-F and\nother documents filed by the Company with the U.S. Securities and Exchange\nCommission. The Company explicitly disclaims any obligation to update any\nforward-looking statements except to the extent required by law.\n\nFor more information, please contact:\nWORK Medical Technology Group LTD\nInvestor Relations Department\nEmail: ir@workmedtech.com\n\nAscent Investor Relations LLC\nTina Xiao\nPhone: +1-646-932-7242\nEmail: investors@ascent-ir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7c9dd1a3-c713-4b34-820d-2c5ef0c0e8b7)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX90RHYp","title":"WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference","author":"Globe Newswire","ticker":"WOK","created":"2026-06-05T13:00:01.622Z","tickers":["WOK"],"exchange":"NASDAQ","article_body":"Deepening Engagement with the Global Biopharmaceutical Community\n\nAuckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical\nTechnology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or\n“we”), a supplier of medical devices in China,today announced its\nparticipation as a partner and exhibitor at the 2026 CBA-China Annual\nConference (the “Conference”), held on May 8 to 10, 2026 in Wuxi, Jiangsu\nProvince, China. The Conference was organized by the Chinese Biopharmaceutical\nAssociation China Branch (CBA-China) and co-hosted by BioValley, bringing\ntogether hundreds of scientists, entrepreneurs, and industry leaders from\nacross the global biopharmaceutical sector.\n\nAs a partner of the Conference, WORK Medical engaged with senior experts from\nNorth America, Europe, and the Asia-Pacific region throughout the three-day\nevent. Discussions focused on global supply chain collaboration, the\napplication of artificial intelligence (“AI”) technologies in life\nsciences, and opportunities for cooperation involving multimodal AI models in\nclinical research and translation.\n\nThe Company’s participation extended beyond showcasing its medical hardware\nand consumables business. WORK Medical also highlighted its strategic\npositioning as a participant in the “AI+Digital Healthcare” sector,\ndemonstrating its evolving focus on AI-driven data enablement and digital\nasset operations. The Company intends to leverage this engagement to establish\nhigh-value strategic partnerships with global industry professionals in areas\nincluding joint technology development and digital asset management.\n\nWORK Medical’s participation in the Conference reflects the Company’s\nbroader strategy of expanding its presence within international professional\nnetworks and strengthening its global industry relationships. The Company\nviews active engagement with the global biopharmaceutical community as an\nimportant component of its international growth strategy, providing insight\ninto emerging clinical needs and facilitating the development of cross-border\npartnerships that may support its future innovation initiatives.\n\nManagement Commentary\n\nMr. Wu Shuang, Chief Executive Officer and Chairman of WORK Medical,\ncommented: “The CBA-China Annual Conference serves as an important platform\nconnecting China’s biopharmaceutical sector with the global scientific\ncommunity. As a Nasdaq-listed company, WORK Medical views continued engagement\nwith leading international medical professionals as an important element of\nour globalization strategy. Through participation in this event, we aim to\nstrengthen our presence within the international professional community,\ndeepen our relationships with industry leaders and gain valuable insight into\nevolving global healthcare trends. We believe these interactions will support\nour efforts to identify future collaboration opportunities and advance our\nlong-term growth strategy.”\n\nAbout WORK Medical Technology Group LTD\n\nWORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou)\nMedical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a\nsupplier of medical devices that develops and manufactures Class I and II\nmedical devices and sells Class I and II disposable medical devices through\noperating subsidiaries in China. The Company has a diverse product portfolio\ncomprising 23 products, including customized and multifunctional masks and\nother medical consumables. All the products have been sold in 34\nprovincial-level administrative regions in China, with 15 of them sold in more\nthan 30 countries worldwide. The Company has received a number of\nquality-related manufacturing designations and has registered 17 products with\nthe U.S. Food and Drug Administration allowing their products to enter the\nU.S. market. For more information, please visit the Company’s website:\nhttps://www.workmedtech.com/corporate.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements, including statements\nmade pursuant to the safe harbor provisions of the Private Securities\nLitigation Reform Act of 1995. These statements may be identified by words\nsuch as “aims,” “anticipates,” “believes,” “could,”\n“estimates,” “expects,” “forecasts,” “goal,” “intends,”\n“may,” “plans,” “possible,” “potential,” “seeks,”\n“will,” and variations of these words or similar expressions that are\nintended to identify forward-looking statements. Any such statements in this\npress release that are not statements of historical fact may be deemed to be\nforward-looking statements. Any forward-looking statements in this press\nrelease are based on the Company’s current expectations, estimates and\nprojections only as of the date of this release and are subject to a number of\nrisks and uncertainties that could cause actual results to differ materially\nand adversely from those set forth in or implied by such forward-looking\nstatements. Although the Company believes that the expectations expressed in\nthese forward-looking statements are reasonable, it cannot assure you that\nsuch expectations will turn out to be correct, and the Company cautions\ninvestors that actual results may differ materially from the anticipated\nresults and encourages investors to review other factors that may affect its\nfuture results set forth in the Company’s annual report on Form 20-F and\nother documents filed by the Company with the U.S. Securities and Exchange\nCommission. The Company explicitly disclaims any obligation to update any\nforward-looking statements except to the extent required by law.\n\nFor more information, please contact:\nWORK Medical Technology Group LTD\nInvestor Relations Department\nEmail: ir@workmedtech.com\n\nAscent Investor Relations LLC\nTina Xiao\nPhone: +1-646-932-7242\nEmail: investors@ascent-ir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7c9dd1a3-c713-4b34-820d-2c5ef0c0e8b7)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-05T13:00:01.677435202Z","server_sent_at_ms":1780664401677},"received_at":"2026-06-05T13:00:01.732Z","source_url":null},"analysis":{"id":"45750","press_release_id":"56322","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"WORK Medical Technology Group participated as a partner and exhibitor at the 2026 CBA-China Annual Conference held in Wuxi, China.\n\nThe company used the platform to engage with global biopharmaceutical experts, focusing on supply chain collaboration and the application of AI in life sciences.\n\nManagement highlighted its strategic positioning in the 'AI+Digital Healthcare' sector and its goal to strengthen international professional networks.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation; no material business updates."},"keyFigures":{"customDimensions":{"product_count":23,"countries_exported":30,"fda_registered_products":17}},"quotedText":"The CBA-China Annual Conference serves as an important platform connecting China’s biopharmaceutical sector with the global scientific community.","namedEntities":{"people":[{"name":"Wu Shuang","role":"CEO and Chairman"},{"name":"Tina Xiao","role":"Investor Relations Contact"}],"products":["medical devices","medical consumables","customized and multifunctional masks"],"companies":[{"name":"WORK Medical Technology Group LTD","ticker":"WOK","relationship":"filer"},{"name":"Chinese Biopharmaceutical Association China Branch","relationship":"conference organizer"},{"name":"BioValley","relationship":"conference co-host"},{"name":"Ascent Investor Relations LLC","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine corporate participation in an industry conference. No new contracts, financial results, or material strategic announcements were disclosed. The release serves primarily as brand visibility and relationship-building."},"tickerRelevance":{"others":[],"primary":"WOK"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"low","sectorWeight":"neutral","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"WORK Medical Technology Group participated as a partner and exhibitor at the 2026 CBA-China Annual Conference held in Wuxi, China.\n\nThe company used the platform to engage with global biopharmaceutical experts, focusing on supply chain collaboration and the application of AI in life sciences.\n\nManagement highlighted its strategic positioning in the 'AI+Digital Healthcare' sector and its goal to strengthen international professional networks.","key_figures":{"customDimensions":{"product_count":23,"countries_exported":30,"fda_registered_products":17}},"named_entities":{"people":[{"name":"Wu Shuang","role":"CEO and Chairman"},{"name":"Tina Xiao","role":"Investor Relations Contact"}],"products":["medical devices","medical consumables","customized and multifunctional masks"],"companies":[{"name":"WORK Medical Technology Group LTD","ticker":"WOK","relationship":"filer"},{"name":"Chinese Biopharmaceutical Association China Branch","relationship":"conference organizer"},{"name":"BioValley","relationship":"conference co-host"},{"name":"Ascent Investor Relations LLC","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-05T13:07:11.951Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"low","sectorWeight":"neutral","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":45463,"modelName":"george-droid-qwen-72b"}}